LCTX — Lineage Cell Therapeutics to Present 36-Month Results from RG6501 (OpRegen) Phase 1/2a Study
Jun 21, 2025, 4:00:00 AM UTC
Summary
Lineage Cell Therapeutics will present 36-month results from the Phase 1/2a clinical study of RG6501 (OpRegen), an allogeneic retinal pigment epithelium (RPE) cell therapy for geographic atrophy secondary to age-related macular degeneration (AMD), at the Clinical Trials at the Summit 2025 on June 21, 2025. The data will be presented by Dr. Christopher D. Riemann on behalf of Roche and Genentech, Lineage's collaborators. OpRegen is being developed as a potential one-time treatment for dry AMD, aiming to address unmet needs in this indication.
Company
LINEAGE CELL THERAPEUTICS INC (LCTX)NYSEMKT — Healthcare: Manufacturing, Biotechnology: Biological Products (No Disgnostic Substances)
www.lineagecell.comSimilar Events
Opus Genetics to Enroll Additional Patients in OPGx-LCA5 Phase 1/2 Study
Opus Genetics plans to enroll additional patients in its ongoing Phase 1/2 clinical trial of OPGx-LCA5, a gene therapy candidate targeting inherited retinal degeneration due to LCA5 mutations. One-year data presented at the 2025 ARVO meeting showed sustained improvements in vision and safety in treated adults. The company is also in discussions with the FDA regarding the registration trial design, aiming to initiate a pivotal study in 2026. OPGx-LCA5 is an investigational gene therapy for inherited retinal diseases, a category of rare genetic disorders causing vision loss.
clinical readoutOPGx-BEST1 IND Filing and Phase 1/2 Trial Initiation
Opus Genetics is set to file an Investigational New Drug (IND) application and initiate a Phase 1/2 clinical trial for OPGx-BEST1, a gene therapy targeting Best disease, an inherited retinal disorder. Early data from the trial is anticipated in Q1 2026, following the company's progress in its gene therapy pipeline for inherited retinal diseases.
clinical readoutExpected Trial Completion for OPGx-001 in LCA5-IRD
Opus Genetics is conducting a phase 1/2 clinical trial of OPGx-001, a gene therapy candidate for LCA5-associated inherited retinal degeneration (LCA5-IRD). The study, which began in June 2023, is expected to complete on January 30, 2028. The trial is a non-randomized, open-label, dose-escalation study evaluating safety and tolerability across three dosing cohorts. OPGx-001 is designed to address a rare genetic cause of vision loss.
trial completionInitial Multi-Patient Data from Pediatric Cohort of LCA5 Study
Opus Genetics anticipates initial multi-patient data from the ongoing pediatric cohort of the LCA5 study in Q3 2025, supporting its gene therapy program for Leber congenital amaurosis 5 (LCA5). This study aims to evaluate the efficacy and safety of the OPGx-LCA5 gene therapy, which has shown promise in restoring vision in patients with this inherited retinal disease.
clinical readout